Sorrento Therapeutics
Sorrento was a San Diego biotech with a sprawling pipeline of antibodies, cell therapies and a resiniferatoxin pain programme for cancer pain; it filed for bankruptcy in 2023.
Overview
Sorrento Therapeutics, founded in 2006 in San Diego, built a broad portfolio spanning antibody libraries, CAR-T and dimeric antigen receptor cell therapies, a Cynviloq paclitaxel formulation and resiniferatoxin for intractable cancer pain, several of which reached phase 3. The company filed for Chapter 11 bankruptcy in 2023 and its assets were sold. Its trials remain on ClinicalTrials.gov under Sorrento as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyIntra-IMMUSG
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyLee's Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.